Universal CAR-T Cells for Rapid Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional vaccines and immunotherapy approaches are ineffective against cancer cells and certain infectious diseases due to their slow immune response and resource depletion over time, leading to inadequate targeting and destruction of unwanted cells.
Innovation Solution
The development of compositions and methods that rapidly and selectively modify cells of the immune system, such as T cells and NK cells, to express targeting agents that bind to specific markers on unwanted cells, allowing for their destruction or protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional vaccines are used to prime the immune system, then the immune system can be directed to target antigens, but the response time is too slow (months to mature) allowing cancer to progress significantly
Solution Approach 1:
The patent applies preliminary action by pre-modifying T-cells ex vivo with chimeric antigen receptors (CARs) before infusion. The T-cells are prepared in advance with the desired targeting capability, eliminating the need for slow in vivo priming. This allows the modified cells to immediately recognize and attack tumor antigens upon infusion, resolving the contradiction between targeting precision and response time.
Solution Approach 2:
The patent uses chimeric antigen receptors (CARs) as intermediaries to bridge the gap between T-cells and tumor antigens. The CAR structure includes an antigen-binding domain (scFv) that specifically recognizes tumor antigens, a transmembrane domain, and intracellular signaling domains. This intermediary mechanism enables rapid and precise targeting without requiring slow natural immune priming.
2Productivity
If autologous T-cell transfer therapy is used to target tumor antigens, then cancer cell destruction is more rapid and potent, but the process is time and labor-intense requiring patient-specific isolation and culturing at specialized centers
Solution Approach 1:
The patent applies universality by developing allogeneic universal CAR-T cell therapies that can treat multiple cancer types with different antigens using a single platform. The modified T-cells are designed to recognize common tumor-associated antigens (such as CD19, CD20, or pan-cancer antigens), allowing one product to serve multiple therapeutic purposes. This reduces the need for complex patient-specific customization while maintaining high cancer cell destruction rates.
Solution Approach 2:
The patent employs disposable allogeneic CAR-T cell products that can be manufactured once and used for multiple patients. Unlike autologous CAR-T cells that require individual patient processing, these universal cells are produced in advance and can be infused into multiple patients without re-engineering, significantly reducing time and labor intensity while maintaining therapeutic effectiveness.
3Reliability
If the immune system is continuously activated to destroy unwanted cells, then therapeutic effectiveness increases, but immune system resources become depleted over time
Solution Approach 1:
The patent applies dynamics by engineering CAR-T cells with controllable activation and persistence characteristics. The cells are designed to remain dormant or at low activity levels until they encounter their target antigen, at which point they become highly active. This dynamic behavior allows the immune system to maintain readiness without continuous activation, preventing resource depletion while ensuring therapeutic effectiveness when needed.
Solution Approach 2:
The patent employs self-service mechanisms where the modified T-cells autonomously seek out and destroy target cells without requiring continuous external immune stimulation. The CAR-T cells express the necessary receptors and effector functions to independently identify, activate against, and eliminate tumor cells, reducing the burden on overall immune system resources while maintaining high therapeutic effectiveness.
Data Source
AI summary
The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.